Evidence map›Paper›PMID 36528448›Full record

ArticleVaccine2024

Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).

Folake Olayinka, Molly Sauer, Lisa Menning, Diane Summers, Chizoba Wonodi, Susan Mackay, Noni E MacDonald, J Peter Figueroa, Benjamin Andriamitantsoa, George Bonsu and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 7 countries.

Folake OlayinkaJSI Research & Training Institute, Inc, Arlington, USA.
Molly SauerDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Lisa MenningDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Diane SummersUNICEF, NY, USA.
Chizoba WonodiDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Susan MackayGavi, the Vaccine Alliance, Geneva, Switzerland.
Noni E MacDonaldDalhousie University, Halifax, Canada.
J Peter FigueroaUniversity of the West Indies, Kingston, Jamaica.
Benjamin AndriamitantsoaFreelance Consultant; Parliament of Madagascar, Antananarivo, Madagascar.
George BonsuExpanded Program on Immunization, Government of Ghana, Accra, Ghana.
Pradeep HaldarMinistry of Health and Family Welfare, Government of India, New Delhi, India.
Ann LindstrandDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Lora ShimpJSI Research & Training Institute, Inc, Arlington, USA. Electronic address: lora_shimp@jsi.com.
IA2030 Strategic Priority 2 Commitment, Demand Working Group
Johns Hopkins University · USWorld Health Organization · CHCatholic University of Madagascar · MGDalhousie University · CAGavi · CHGovernment of Ghana · GHGovernment of India · INUnited Nations Children's Fund · USUniversity of the West Indies · JM

Funding

World Health Organization 001
6 · The paper itself

Abstract

Vaccines have contributed to substantial improvements in health and social development outcomes for millions in recent decades. However, equitable access to immunization remains a critical challenge that has stalled progress toward improving several health indicators around the world. The COVID-19 pandemic has also negatively impacted routine immunization services around the world further threatening universal access to the benefits of lifesaving vaccines. To overcome these challenges, the Immunization Agenda 2030 (IA2030) focuses on increasing both commitment and demand for vaccines. There are three broad barriers that will need to be addressed in order to achieve national and subnational immunization targets: (1) shifting leadership priorities and resource constraints, (2) visibility of disease burden, and (3) social and behavioral drivers. IA2030 proposes a set of interventions to address these barriers. First, efforts to ensure government engagement on immunization financing, regulatory, and legislative frameworks. Next, those in subnational leadership positions and local community members need to be further engaged to ensure local commitment and demand. Governance structures and health agencies must accept responsibility and be held accountable for delivering inclusive, quality, and accessible services and for achieving national targets. Further, the availability of quality immunization services and commitment to adequate financing and resourcing must go hand-in-hand with public health programs to increase access to and demand for vaccination. Last, strengthening trust in immunization systems and improving individual and program resilience can help mitigate the risk of vaccine confidence crises. These interventions together can help ensure a world where everyone, everywhere has access to and uses vaccines for lifesaving vaccination.

Indexed as

COVID-19Immunization ProgramsVaccinationCOVID-19 VaccinesGlobal HealthHealth PolicyHumansImmunizationLeadershipPandemicsPoliticsSARS-CoV-2COVID-19 VaccinesAcceptanceCommitmentDemandVaccination

Identifiers

PMID36528448
PMCPMC11413528
OpenAlexW4311749414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.